2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse @wearesrna
2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse  @wearesrna
Uploaded October 2026 | Updated November 2026, 3 hours ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Linda Nguyen, MD, PhD, of UT Southwestern Medical Center and Children's Health, spoke about predicting relapse in children with MOG antibody disease (MOGAD) [00:00:52]. She explained why some children have a single attack while others relapse, the question of starting preventive treatment, and what earlier studies have found [00:01:16]. She described a study across three pediatric centers in the United States, with 225 children identified and 187 followed for at least six months [00:05:42]. Dr. Nguyen reported that 31 percent relapsed, when relapses happened, and which first-attack features mattered, including acute disseminated encephalomyelitis (ADEM) combined with another presentation [00:08:25]. She showed that repeat MOG antibody tests months after the first attack were the strongest clue, with negative or low results reassuring and higher titers linked to more relapses [00:15:00].

Linda Nguyen, MD, PhD, is an Assistant Professor of Pediatrics at UT Southwestern Medical Center and Children's Health in Dallas, Texas. She completed her MD and PhD training at West Virginia University in 2017, a pediatric neurology residency at UC San Diego in 2022, and a neuroimmunology fellowship at UT Southwestern.

00:00 Introduction
00:52 Predicting Relapse in Children
01:16 What the Talk Will Cover
02:48 What Earlier Studies Found
05:42 What This Study Adds
06:51 The Two Research Questions
08:25 How Many Children Relapsed
09:55 First-Attack Clues
15:00 Antibody Tests Over Time
17:34 Key Takeaways
18:33 Limits and Next Steps
2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse2025 RNDS | Upcoming therapies for MOGAD and NMOSD: Long-term therapeutics1311.  Understanding Myelitis: Efforts to Update Diagnostic Criteria2025 RNDS | Addressing Mental Health and Rare Neuroimmune DisordersAsk the Expert 1401. Open Q&A on Neuromyelitis Optica Spectrum Disorder (NMOSD)The Power of Community: Abby2026 RNDS | State of the Science Across Rare Neuroimmune Disorders and Clinical Trials Panel1114. Neurosarcoidosis and Rare Neuroimmune Disorders2025 RNDS | Patient and care partner panel2026 RNDS | Pain and Sensory Symptoms Toolkit2025 RNDS | Open Q&A with SRNA James T. Lubin Fellows2025 RNDS | Welcome Remarks
SRNA |

2026 RNDS | Research on Predicting MOGAD Patients at Risk for Relapse

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER